Apoc2

Summary

Gene Symbol: Apoc2
Description: apolipoprotein C2
Alias: RGD1560725, apolipoprotein C-II
Species: rat
Products:     Apoc2

Top Publications

  1. Kajinami K, Mabuchi H, Koizumi J, Takeda R. Serum apolipoproteins in heterozygous familial hypercholesterolemia. Clin Chim Acta. 1992;211:93-9 pubmed
    ..34 +/- 0.07) was significantly lower than that in normal subjects (0.39 +/- 0.05). This difference might possibly be produced by an abnormal HDL metabolism of FH patients, a topic which remains to be elucidated by further investigation...
  2. Lam C, Yuen Y, Cheng W, Chan Y, Tong S. Missense mutation Leu72Pro located on the carboxyl terminal amphipathic helix of apolipoprotein C-II causes familial chylomicronemia syndrome. Clin Chim Acta. 2006;364:256-9 pubmed
    ..the molecular basis of chylomicronemia syndrome in this family, we performed direct DNA sequencing of the LPL and APOC2 genes of the proband...
  3. Ren Y, Tian H, Liu B, Liang J, Zhang X, Yao J, et al. [The abnormal changes of apolipoprotein(s) in patients with type 2 diabetes mellitus]. Hua Xi Yi Ke Da Xue Xue Bao. 2001;32:48-51, 69 pubmed
    ..Abnormal changes of apo(s) in type 2 diabetes mellitus may be a cause of type 2 diabetes associated with HTG and CHD. ..
  4. Pham C, Hatters D, Lawrence L, Howlett G. Cross-linking and amyloid formation by N- and C-terminal cysteine derivatives of human apolipoprotein C-II. Biochemistry. 2002;41:14313-22 pubmed
    ..These data suggest that the N- and C-termini of apoC-II are close together in the amyloid fibril such that covalent cross-linking of either the N or C end of apoC-II promotes nucleation and the "seeding" of fibril growth. ..
  5. Konemori G, Kawanishi M, Nakamoto A, Hiraoka M, Kajiyama G. [Application of the box plot to evaluate serum lipid levels and apolipoprotein levels in patients with cerebral infarction and diabetes mellitus]. Nihon Ronen Igakkai Zasshi. 1990;27:22-7 pubmed
    ..d. Compared to the control group, the ratio of LDL-C. to Apo B was lower (p less than 0.05) in the cerebral infarction group with diabetes mellitus and tended to be lower even in the diabetes mellitus-only group. ..
  6. Andersson Y, Majd Z, Lefebvre A, Martin G, Sechkin A, Kosykh V, et al. Developmental and pharmacological regulation of apolipoprotein C-II gene expression. Comparison with apo C-I and apo C-III gene regulation. Arterioscler Thromb Vasc Biol. 1999;19:115-21 pubmed
  7. Kinnunen P, Ehnolm C. Effect of serum and C-apoproteins from very low density lipoproteins on human postheparin plasma hepatic lipase. FEBS Lett. 1976;65:354-7 pubmed
  8. Takahashi H, Hashimoto N, Kawasaki T, Kikuchi T, Uchiyama M. The usefulness of measuring body fat deposition for detecting obesity and atherogenesity in Japanese school children. Acta Paediatr Jpn. 1996;38:634-9 pubmed
    ..low-density lipoprotein cholesterol (LDL-C), atherogenic index (AI), RLP-cholesterol (RLP-C), apoA1, apoA2, apoB, apoC2, apoC3, apoE and the ratio of apoB to apoA1 than non-overweight boys...
  9. Meyer B, Duvillard L, Owen A, Packard C, Caslake M. Fractionation of cholesteryl ester rich intermediate density lipoprotein subpopulations by chondroitin sulphate. Atherosclerosis. 2007;195:e28-34 pubmed
    ..It remains to be determined if these cholesterol rich IDL particles are potentially more atherogenic than the triglyceride rich IDL particles. ..
  10. Pogoda T, Nikonova A, Kolosova T, Liudvikova E, Perova N, Limborskaia S. [Allelic variants of apolipoproteins B and CII genes in patients with ischemic heart disease and in healthy persons from the Moscow population]. Genetika. 1995;31:1001-9 pubmed
    ..Individuals of the control group with the allele APOCII 30 exhibited hypertriglyceridemia without increased levels of total cholesterol and apolipoprotein B in plasma. ..

Detail Information

Publications32

  1. Kajinami K, Mabuchi H, Koizumi J, Takeda R. Serum apolipoproteins in heterozygous familial hypercholesterolemia. Clin Chim Acta. 1992;211:93-9 pubmed
    ..34 +/- 0.07) was significantly lower than that in normal subjects (0.39 +/- 0.05). This difference might possibly be produced by an abnormal HDL metabolism of FH patients, a topic which remains to be elucidated by further investigation...
  2. Lam C, Yuen Y, Cheng W, Chan Y, Tong S. Missense mutation Leu72Pro located on the carboxyl terminal amphipathic helix of apolipoprotein C-II causes familial chylomicronemia syndrome. Clin Chim Acta. 2006;364:256-9 pubmed
    ..the molecular basis of chylomicronemia syndrome in this family, we performed direct DNA sequencing of the LPL and APOC2 genes of the proband...
  3. Ren Y, Tian H, Liu B, Liang J, Zhang X, Yao J, et al. [The abnormal changes of apolipoprotein(s) in patients with type 2 diabetes mellitus]. Hua Xi Yi Ke Da Xue Xue Bao. 2001;32:48-51, 69 pubmed
    ..Abnormal changes of apo(s) in type 2 diabetes mellitus may be a cause of type 2 diabetes associated with HTG and CHD. ..
  4. Pham C, Hatters D, Lawrence L, Howlett G. Cross-linking and amyloid formation by N- and C-terminal cysteine derivatives of human apolipoprotein C-II. Biochemistry. 2002;41:14313-22 pubmed
    ..These data suggest that the N- and C-termini of apoC-II are close together in the amyloid fibril such that covalent cross-linking of either the N or C end of apoC-II promotes nucleation and the "seeding" of fibril growth. ..
  5. Konemori G, Kawanishi M, Nakamoto A, Hiraoka M, Kajiyama G. [Application of the box plot to evaluate serum lipid levels and apolipoprotein levels in patients with cerebral infarction and diabetes mellitus]. Nihon Ronen Igakkai Zasshi. 1990;27:22-7 pubmed
    ..d. Compared to the control group, the ratio of LDL-C. to Apo B was lower (p less than 0.05) in the cerebral infarction group with diabetes mellitus and tended to be lower even in the diabetes mellitus-only group. ..
  6. Andersson Y, Majd Z, Lefebvre A, Martin G, Sechkin A, Kosykh V, et al. Developmental and pharmacological regulation of apolipoprotein C-II gene expression. Comparison with apo C-I and apo C-III gene regulation. Arterioscler Thromb Vasc Biol. 1999;19:115-21 pubmed
  7. Kinnunen P, Ehnolm C. Effect of serum and C-apoproteins from very low density lipoproteins on human postheparin plasma hepatic lipase. FEBS Lett. 1976;65:354-7 pubmed
  8. Takahashi H, Hashimoto N, Kawasaki T, Kikuchi T, Uchiyama M. The usefulness of measuring body fat deposition for detecting obesity and atherogenesity in Japanese school children. Acta Paediatr Jpn. 1996;38:634-9 pubmed
    ..low-density lipoprotein cholesterol (LDL-C), atherogenic index (AI), RLP-cholesterol (RLP-C), apoA1, apoA2, apoB, apoC2, apoC3, apoE and the ratio of apoB to apoA1 than non-overweight boys...
  9. Meyer B, Duvillard L, Owen A, Packard C, Caslake M. Fractionation of cholesteryl ester rich intermediate density lipoprotein subpopulations by chondroitin sulphate. Atherosclerosis. 2007;195:e28-34 pubmed
    ..It remains to be determined if these cholesterol rich IDL particles are potentially more atherogenic than the triglyceride rich IDL particles. ..
  10. Pogoda T, Nikonova A, Kolosova T, Liudvikova E, Perova N, Limborskaia S. [Allelic variants of apolipoproteins B and CII genes in patients with ischemic heart disease and in healthy persons from the Moscow population]. Genetika. 1995;31:1001-9 pubmed
    ..Individuals of the control group with the allele APOCII 30 exhibited hypertriglyceridemia without increased levels of total cholesterol and apolipoprotein B in plasma. ..
  11. Kinnunen P, Jackson R, Smith L, Gotto A, Sparrow J. Activation of lipoprotein lipase by native and synthetic fragments of human plasma apolipoprotein C-II. Proc Natl Acad Sci U S A. 1977;74:4848-51 pubmed
    ..These studies suggest that the maximal activation of LPL by apoC-II requires a minimal sequence contained within residues 55--78. ..
  12. Hughes T, Gaber A, Amiri H, Wang X, Elmer D, Winsett R, et al. Lipoprotein composition in insulin-dependent diabetes mellitus with chronic renal failure: effect of kidney and pancreas transplantation. Metabolism. 1994;43:333-47 pubmed
    ..The addition of a pancreas to a kidney transplant had no obvious impact on the lipoproteins.(ABSTRACT TRUNCATED AT 400 WORDS)..
  13. Lontie J, Malmendier C, Serougne C, Dubois D, Dachet C, Ferezou J, et al. Plasma lipids, lipoproteins and apolipoproteins in two kindreds of hypobetalipoproteinemia. Atherosclerosis. 1990;83:187-96 pubmed
    ..Due to the net reduction of apolipoprotein B-containing particles (VLDL and LDL) as acceptors of lipids in HBL, there is an accumulation of large particles rich in cholesteryl esters. ..
  14. Sehayek E, Eisenberg S. Mechanisms of inhibition by apolipoprotein C of apolipoprotein E-dependent cellular metabolism of human triglyceride-rich lipoproteins through the low density lipoprotein receptor pathway. J Biol Chem. 1991;266:18259-67 pubmed
  15. Windler E, Havel R. Inhibitory effects of C apolipoproteins from rats and humans on the uptake of triglyceride-rich lipoproteins and their remnants by the perfused rat liver. J Lipid Res. 1985;26:556-65 pubmed
    ..Preferential loss of apolipoprotein C-II during remnant formation may regulate the termination of triglyceride hydrolysis prior to complete removal of triglycerides from chylomicrons and VLDL. ..
  16. Zysow B, Pullinger C, Hennessy L, Farese R, Ghassemzadeh M, Kane J. The apolipoprotein C-II variant apoC-IILys19-->Thr is not associated with dyslipidemia in an affected kindred. Clin Genet. 1994;45:292-7 pubmed
    ..The single nucleotide substitution-that causes the apoC-IILys19-->Thr variant introduces a previously unrecognized restriction site (for Mae III), that provides for easy screening. ..
  17. Joven J, Villabona C, Vilella E. Pattern of hyperlipoproteinemia in human nephrotic syndrome: influence of renal failure and diabetes mellitus. Nephron. 1993;64:565-9 pubmed
  18. Baggio G, Manzato E, Gabelli C, Fellin R, Martini S, Enzi G, et al. Apolipoprotein C-II deficiency syndrome. Clinical features, lipoprotein characterization, lipase activity, and correction of hypertriglyceridemia after apolipoprotein C-II administration in two affected patients. J Clin Invest. 1986;77:520-7 pubmed
    ..A possible therapeutic role for replacement therapy of apo C-II by synthetic or recombinant apo C-II in those patients with severe hypertriglyceridemia and recurrent pancreatitis may be possible in the future. ..
  19. Pan X, Cheung M, Walden C, Hu S, Bierman E, Albers J. Abnormal composition of apoproteins C-I, C-II, and C-III in plasma and very-low-density lipoproteins of non-insulin-dependent diabetic Chinese. Clin Chem. 1986;32:1914-20 pubmed
    ..Therefore, the higher concentrations of very-low-density lipoprotein in male diabetics may not reflect hyperglycemia per se. ..
  20. Zouali H, Faure Delanef L, Lucotte G. Chromosome 19 locus apolipoprotein C-II association with multiple sclerosis. Mult Scler. 1999;5:134-6 pubmed
    ..04) with MS due to the increased frequency of the allele 6 and a decrease frequency (P < 0.03) of allele I. Our study confirms that the apolipoprotein C-II region may influence susceptibility to MS. ..
  21. Mak P, Laffitte B, Desrumaux C, Joseph S, Curtiss L, Mangelsdorf D, et al. Regulated expression of the apolipoprotein E/C-I/C-IV/C-II gene cluster in murine and human macrophages. A critical role for nuclear liver X receptors alpha and beta. J Biol Chem. 2002;277:31900-8 pubmed
    ..These results suggest an alternative mechanism by which lipids are removed from macrophage foam cells. ..
  22. Kardassis D, Roussou A, Papakosta P, Boulias K, Talianidis I, Zannis V. Synergism between nuclear receptors bound to specific hormone response elements of the hepatic control region-1 and the proximal apolipoprotein C-II promoter mediate apolipoprotein C-II gene regulation by bile acids and retinoids. Biochem J. 2003;372:291-304 pubmed
  23. Christoffersen C, Nielsen L, Axler O, Andersson A, Johnsen A, Dahlback B. Isolation and characterization of human apolipoprotein M-containing lipoproteins. J Lipid Res. 2006;47:1833-43 pubmed
    ..Nevertheless, apoM designates a subpopulation of HDL that protects LDL against oxidation and stimulates cholesterol efflux more efficiently than HDL lacking apoM. ..
  24. Pullinger C, Zysow B, Hennessy L, Frost P, Malloy M, Kane J. Molecular cloning and characteristics of a new apolipoprotein C-II mutant identified in three unrelated individuals with hypercholesterolemia and hypertriglyceridemia. Hum Mol Genet. 1993;2:69-74 pubmed
    ..The presence of other factors acting together with the variant may predispose to elevated lipid levels. ..
  25. Huard K, Bourgeois P, Rhainds D, Falstrault L, Cohn J, Brissette L. Apolipoproteins C-II and C-III inhibit selective uptake of low- and high-density lipoprotein cholesteryl esters in HepG2 cells. Int J Biochem Cell Biol. 2005;37:1308-18 pubmed
    ..These results indicate that apoC-II and apoC-III inhibit CE-selective uptake. ..
  26. Pulawa L, Jensen D, Coates A, Eckel R. Reduction of plasma triglycerides in apolipoprotein C-II transgenic mice overexpressing lipoprotein lipase in muscle. J Lipid Res. 2007;48:145-51 pubmed
    ..Furthermore, the decrease of LPL activity in the heart, along with the inhibitory effects of excess apoC-II, may contribute to the hypertriglyceridemia observed in apoC-II transgenic mice. ..
  27. Jong M, Hofker M, Havekes L. Role of ApoCs in lipoprotein metabolism: functional differences between ApoC1, ApoC2, and ApoC3. Arterioscler Thromb Vasc Biol. 1999;19:472-84 pubmed
  28. MacPhee C, Hatters D, Sawyer W, Howlett G. Apolipoprotein C-II39-62 activates lipoprotein lipase by direct lipid-independent binding. Biochemistry. 2000;39:3433-40 pubmed
  29. Lookene A, Beckstead J, Nilsson S, Olivecrona G, Ryan R. Apolipoprotein A-V-heparin interactions: implications for plasma lipoprotein metabolism. J Biol Chem. 2005;280:25383-7 pubmed
    ..Through such interactions, apoA-V may indirectly affect LPL activity, possibly explaining its inverse correlation with plasma TG levels. ..
  30. Hegele R, Connelly P, Maguire G, Huff M, Leiter L, Wolfe B, et al. An apolipoprotein CII mutation, CIILys19----Thr' identified in patients with hyperlipidemia. Dis Markers. 1991;9:73-80 pubmed
  31. Remaley A, Stonik J, Demosky S, Neufeld E, Bocharov A, Vishnyakova T, et al. Apolipoprotein specificity for lipid efflux by the human ABCAI transporter. Biochem Biophys Res Commun. 2001;280:818-23 pubmed
    ..In summary, ABCAI-mediated cellular binding of apolipoproteins and lipid efflux is not specific for only apoA-I but can also occur with other apolipoproteins that contain multiple amphipathic helical domains...
  32. Connelly P, Maguire G, Vezina C, Hegele R, Little J. Identification of disulfide-linked apolipoprotein species in human lipoproteins. J Lipid Res. 1993;34:1717-27 pubmed
    ..These results demonstrate that the molecular species of cysteine-containing apolipoproteins are complex and should be considered in studies of human lipoprotein composition and function. ..